Abstract
A long-standing paradigm in drug discovery has been the concept of designing maximally selective drugs to act on individual targets considered to underlie a disease of interest. Nonetheless, although some drugs have proven to be successful, many more potential drugs identified by the “one gene, one drug, one disease" approach have been found to be less effective than expected or to cause notable side effects. Advances in systems biology and high-throughput in-depth genomic profiling technologies along with an analysis of the successful and failed drugs uncovered that the prominent factor to determine drug sensitivity is the intrinsic robustness of the response of biological systems in the face of perturbations. The complexity of the molecular and cellular bases of systems responses to drug interventions has fostered an increased interest in systems-oriented approaches to drug discovery. Consonant with this knowledge of the multifactorial mechanistic basis of drug sensitivity and resistance is the application of network-based approaches for the identification of molecular (multi-)feature signatures associated with desired (multi-)drug phenotypic profiles. This chapter illustrates the principal network analysis and inference techniques which have found application in systems-oriented drug design and considers their benefits and drawbacks in relation to the nature of the data produced by network pharmacology.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Kitano H (2002) Systems biology: a brief overview. Science 295:1662–1664
Barabási AL, Oltvai ZN (2004) Network biology: understanding the cell’s functional organization. Nat Rev Genet 5:101–113
Cormen TH, Leiserson CE, Rivest RL, Stein C (2001) Introduction to algorithms, 2nd edn. MIT Press and McGraw-Hill Book Company, Cambridge, MA
Kitano H (2001) Exploring complex networks. Nature 410:268–276
Palla G, Derényi I, Farkas I, Vicsek T (2005) Uncovering the overlapping community structure of complex networks in nature and society. Nature 435:814–818
Al-Lazikani B, Banerji U, Workman P (2012) Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 30:679–692
Keith CT, Borisy AA, Stockwell BR (2005) Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 4:71–78
Foucquier J, Guedj M (2015) Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect 3:e00149
Kitano H (2004) Biological robustness. Nat Rev Genet 5:826–837
Stelling J, Sauer U, Szallasi Z et al (2004) Robustness of cellular functions. Cell 118:675–685
Alon U (2007) Network motifs: theory and experimental approaches. Nat Rev Genet 8:450–461
Vidal M, Cusick ME, Barabási AL (2011) Interactome networks and human disease. Cell 144:986–998
Covell DG (2015) Data mining approaches for genomic biomarker development: applications using drug screening data from the cancer genome project and the cancer cell line encyclopedia. PLoS One 10, e0127433
Lamb J, Crawford ED, Peck D et al (2006) The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313:1929–1935
Woo JH, Shimoni Y, Yang WS et al (2015) Elucidating compound mechanism of action by network perturbation analysis. Cell 162:441–451
Zhu M, Gao L, Li X et al (2009) The analysis of the drug-targets based on the topological properties in the human protein-protein interaction network. J Drug Target 17:524–532
Jeong H, Mason SP, Barabśi AL, Oltvai ZN (2001) Lethality and centrality in protein networks. Nature 411:41–42
Khuri S, Wuchty S (2012) Essentiality and centrality in protein interaction networks revisited. BMC Bioinformatics 16:109
Brush ER, Krakauer DC, Flack JC (2013) A family of algorithms for computing consensus about node state from network data. PLoS Comput Biol 9:e1003109
Yang L, Wang J, Wang H et al (2014) Characterization of essential genes by topological properties in the perturbation sensitivity network. Biochem Biophys Res Commun 448:473–479
Wang X, Thijssen B, Yu H (2013) Target essentiality and centrality characterize drug side effects. PLoS Comput Biol 9:e1003119
Peng Q, Schork NJ (2014) Utility of network integrity methods in therapeutic target identification. Front Genet 5:12
Barzel B, Barabási AL (2013) Universality in network dynamics. Nat Phys 9
Estrada E (2012) The structure of complex networks. Theory and applications, 1st edn. Oxford University Press, Oxford, UK
Sams-Dodd F (2005) Target-based drug discovery: is something wrong? Drug Discov Today 10:139–147
Kitano H (2010) Violations of robustness trade-offs. Mol Syst Biol 6
Kassouf W, Dinney CP, Brown G et al (2005) Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of gefitinib in bladder cancer cells. Cancer Res 65(10):524–535
Sergina NV, Rausch M, Wang D et al (2007) Escape from her-family tyrosine kinase inhibitor therapy by the kinase-inactive her3. Nature 445:437–441
Meng J, Peng H, Dai B et al (2009) High level of akt activity is associated with resistance to mek inhibitor azd6244 (arry-142886). Cancer Biol Ther 8:2073–2080
Rodrik-Outmezguine VS, Chandarlapaty S, Pagano NC et al (2011) mTOR kinase inhibition causes feedback-dependent biphasic regulation of akt signaling. Cancer Discov 1:248–259
FitzGerald GA, Patrono C (2001) The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345:433–442
Ito T, Ando H, Suzuki T et al (2010) Identification of a primary target of thalidomide teratogenicity. Science 327:1345–1350
Jia J, Zhu F, Ma X et al (2009) Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov 8:111–128
Modi S, Stopeck A, Linden H et al (2011) Hsp90 inhibition is effective in breast cancer: a phase ii trial of tanespimycin (17-aag) plus trastuzumab in patients with her2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 17:5132–5139
Nahta R, Hung MC, Esteva FJ (2004) The her-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64:2343–2346
Meng J, Dai B, Fang B et al (2010) Combination treatment with mek and akt inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. Cell 5:e14124
Hopkins AL (2008) Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4:682–690
Pe’er D, Hacohen N (2011) Principles and strategies for developing network models in cancer. Cell 144:864–873
Zotenko E, Mestre J, O’Leary DP et al (2008) Why do hubs in the yeast protein interaction network tend to be essential: reexamining the connection between the network topology and essentiality. PLoS Comput Biol 4:e1000140
Yu H, Kim PM, Sprecher E et al (2007) The importance of bottlenecks in protein networks: correlation with gene essentiality and expression dynamics. PLoS Comput Biol 3:e59
Hwang WC, Zhang A, Ramanathan M (2008) Identification of information flow-modulating drug targets: a novel bridging paradigm for drug discovery. Clin Pharmacol Ther 84:563–572
Nacher JC, Schwartz JM (2008) A global view of drug-therapy interactions. BMC Pharmacol 8
Almaas E, Kovács B, Vicsek T et al (2004) Global organization of metabolic fluxes in the bacterium Escherichia coli. Nature 427:839–843
Csermely P (2004) Strong links are important, but weak links stabilize them. Trends Biochem Sci 29:331–334
Zhang X, Zhang Z, Zhao H et al (2014) Extracting the globally and locally adaptive backbone of complex networks. PLoS One 9:e100428
Estrada E, Hatano N (2010) A vibrational approach to node centrality and vulnerability in complex networks. Physica A 389:3648–3660
Birtwistle MR, Hatakeyama M, Yumoto N et al (2007) Ligand-dependent responses of the erbb signaling network: experimental and modeling analyses. Mol Syst Biol 3:144
Iadevaia S, Lu Y, Morales FC et al (2010) Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res 70:6704–6714
Chou IC, Voit EO (2009) Recent developments in parameter estimation and structure identification of biochemical and genomic systems. Math Biosci 219:57–83
Liu Y, Gunawan R (2014) Parameter estimation of dynamic biological network models using integrated fluxes. BMC Syst Biol 8:127
Faratian D, Goltsov A, Lebedeva G et al (2009) Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of pten in resistance to trastuzumab. Cancer Res 69:6713–6720
Morris MK, Saez-Rodriguez J, Sorger PK, Lauffenburger DA (2010) Logic-based models for the analysis of cell signaling networks. Biochemistry 49:3216–3224
Lee MJ, Ye AS, Gardino AK et al (2012) Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 149:780–794
Sahin O, Fröhlich H, Löbke C et al (2009) Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance. BMC Syst Biol 3:1
Aldridge BB, Saez-Rodriguez J, Muhlich JL et al (2009) Fuzzy logic analysis of kinase pathway crosstalk in TNF/EGF/insulin-induced signaling. PLoS Comput Biol 5:e1000340
Sachs K, Perez O, Pe’er D et al (2005) Causal protein-signaling networks derived from multiparameter single-cell data. Science 308:523–529
Barretina J, Caponigro G, Stransky N et al (2012) The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603–607
Shoemaker RH (2006) The nci60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6:813–823
Pal R, Berlow N (2012) A kinase inhibition map approach for tumor sensitivity prediction and combination therapy design for targeted drugs. Pac Symp Biocomput. pp 351–362
Tang J, Karhinen L, Xu T et al (2013) Target inhibition networks: Predicting selective combinations of druggable targets to block cancer survival pathways. PLoS Comput Biol 9:e1003226
Ranjan G, Zhang ZL (2013) Geometry of complex networks and topological centrality. Physica A 392:3833–3845
Estrada E, Hatano H (2010) Resistance distance, information centrality, node vulnerability and vibrations in complex networks. In: Estrada E, Fox M, Higham D, Oppo GL (eds) Network science: complexity in nature and technology. Springer, New York, pp 13–29
Yang W, Soares J, Greninger P et al (2013) Genomics of drug sensitivity in cancer (gdsc): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res 41(Database issue):D955–61
Cappuccio A, Zollinger R, Schenk M et al (2015) Combinatorial code governing cellular responses to complex stimuli. Nat Commun 6:e0127433
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media New York
About this protocol
Cite this protocol
Lecca, P., Re, A. (2017). Network-Oriented Approaches to Anticancer Drug Response. In: Kasid, U., Clarke, R. (eds) Cancer Gene Networks. Methods in Molecular Biology, vol 1513. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6539-7_8
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6539-7_8
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6537-3
Online ISBN: 978-1-4939-6539-7
eBook Packages: Springer Protocols